Q&A: Roche responds to the community
Q&A from Roche: Roche response to community questions regarding their recent decision to not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome. With logos for FAST and ASF

Roche has responded to our request by answering questions from the community regarding their recent decision to not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome. 

Questions & Answers from Roche

Please consider joining the ASF/FAST hosted webinar on July 7 at 12pm ET with Dr. Elizabeth Berry-Kravis, a principal investigator for the Roche (Tangelo) program.

Click here to register for the webinar.

Share
Facebook
Twitter
LinkedIn
Email
Foundation Updates
Q&A with new development advisor Elizabeth O’Connor
Q&A with new development advisor Elizabeth O’Connor
RARE Compassion Program Update
RARE Compassion Program Update
Research Updates
New publication supported by FAST and ABOM about the Vineland Adaptive Behavior Scales
New publication supported by FAST and ABOM about the Vineland Adaptive Behavior Scales
Register for the Global Angelman Syndrome Registry
Register for the Global Angelman Syndrome Registry